首页|基于TCGA数据库分析葡萄糖代谢相关基因与乳腺癌临床病理特性及预后相关性

基于TCGA数据库分析葡萄糖代谢相关基因与乳腺癌临床病理特性及预后相关性

Glucose metabolism-related genes with clinicopathological characteristics and prognosis of breast cancer:an analysis based on TCGA database

扫码查看
目的 探究乳酸脱氢酶A(LDHA)、溶质载体家族16成员(SLC16A)1及SLC16A3基因与乳腺癌病理特征及预后的关系.方法 获取肿瘤基因组图谱数据库(TCGA)中1 060位乳腺癌患者的组织样本,分析LDHA、SLC16A1及SLC16A3基因表达量与乳腺癌临床病理特征及预后的关联性,用Kaplan-Meier生存分析绘制生存曲线,Cox比例风险回归模型进行单因素和多因素生存预后分析.结果 LDHA表达与远处转移(M分期)(χ2=5.560,P=0.018)、雌激素受体(ER)表达(χ2=8.532,P=0.003)、人表皮生长因子受体-2(HER-2)表达(χ2=4.418,P=0.036)相关;SLC16A1 表达与年龄(χ2=8.040,P=0.005)、ER 表达(χ2=17.428,P<0.01)、孕激素受体(PR)表达(χ2=5.486,P=0.019)相关;SLC16A3 表达与 ER 表达(χ2=22.447,P<0.01)、PR 表达(χ2=20.590,P<0.01)相关.LDHA(χ2=3.856,P=0.049)、SLC16A1(χ2=3.978,P=0.046)和 SLC16A3(χ2=5.008,P=0.025)高表达患者较低表达患者累积生存率更低.SLC16A1(HR=1.894,95%CI:1.246~2.878,P=0.003)和 SLC16A3(HR=1.769,95%CI:1.009~2.847,P=0.019)是乳腺癌患者总生存时间的独立危险因素.结论 LDHA、SLC16A1及SLC16A3基因与乳腺癌某些病理特征及较差的预后相关,可能为乳腺癌治疗提供新的预后指标和治疗靶点.
Objective To investigate the relationship between the expression of LDHA,SLC16A1 and SLC16A3 genes and pathologic features and prognosis in breast cancer.Methods Tissue samples from 1 060 breast cancer patients in The Cancer Genome Atlas(TCGA)were obtained.The association of LDHA,SLC16A1 and SLC16A3 gene expressions with clinicopathological features and prognosis of breast cancer were analyzed.Survival curve were drawn by Kaplan-Meier survival analysis,and univariable and multivariable survival prognosis were analyzed by Cox proportional hazard regression model.Results LDHA expression was associated with distant metastasis(M stage)(χ2=5.560,P=0.018),estrogen receptor(ER)expression(χ2=8.532,P=0.003),and human epidermal growth factor receptor 2(HER-2)expression(χ2=4.418,P=0.036);SLC16A1 expression correlated with age(χ2=8.040,P=0.005),ER expression(χ2=17.428,P<0.01),and progesterone receptor(PR)expression(χ2=5.486,P=0.019).SLC16A3 expression correlated with ER expression(χ2=22.447,P<0.01),PR expression(χ2=20.590,P<0.01).Patients with high expression of LDHA(χ2=3.856,P=0.049),SLC16A1(χ2=3.978,P=0.046)and SLC16A3(χ2=5.008,P=0.025)had lower cumulative survival rates.SLC16A1(HR=1.894,95%CI:1.246-2.878,P=0.003)and SLC16A3(HR=1.769,95%CI:1.009-2.847,P=0.019)were the independent risk factors for overall survival in breast cancer patients.Conclusion LDHA,SLC16A1 and SLC16A3 are associated with certain pathologic features and poorer prognosis of breast cancer,which may provide new prognostic indicators and therapeutic targets for breast cancer treatment.

Breast cancerGlucose metabolismLactate dehydrogenase ASolute carrier family 16 member 1Solute carrier family 16 member 3Overall survival

夏娟娟、许靖童、管晓翔

展开 >

南京医科大学附属苏州医院肿瘤内科,江苏苏州 215000

南京医科大学第一附属医院肿瘤科,江苏南京 210000

乳腺癌 葡萄糖代谢 乳酸脱氢酶A 溶质载体家族16成员1 溶质载体家族16成员3 总生存率

江苏省重点研发计划社会发展专项

BE2021741

2024

中国临床研究
中华预防医学会

中国临床研究

CSTPCD
影响因子:0.943
ISSN:1674-8182
年,卷(期):2024.37(3)
  • 29